BioAge Labs (BIOA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BIOA · Stock Price

USD 17.82+13.78 (+341.09%)

Market Cap: $800.0M

Historical price data

Market Cap: $800.0MPipeline: 4 drugsPatents: 9Founded: 2015Employees: 51-200HQ: Emeryville, United States

Sector Ranking#21 in AI / Machine Learning #193 in Small Molecule Drugs

Overview

Founded in 2015, BioAge Labs leverages its proprietary multi-omics discovery platform to translate insights from human aging biology into a pipeline of novel therapeutics for metabolic diseases. The company has achieved key milestones, including advancing its lead oral NLRP3 inhibitor, BGE-102, into Phase 1b/2a studies for cardiovascular risk and diabetic macular edema, and preparing an IND for its apelin receptor agonist as an exercise mimetic. Its strategy is validated by a recent $115 million public offering, positioning it to execute on its clinical and platform expansion goals through 2026.

MetabolicCardiovascularOphthalmology

Technology Platform

A proprietary human-first discovery platform that analyzes decades of longitudinal human multi-omics data to identify and validate causal molecular mediators of aging as novel drug targets for metabolic diseases.

Pipeline

4

4 drugs in pipeline

Drug	Indication	Stage
BGE-117	Anemia	Phase 2
BGE-175	Covid19	Phase 2
BGE-117, 4mg + BGE-117, 12mg	Acute Posthemorrhagic Anemia	Phase 2
Azelaprag	Healthy Volunteer Study	Phase 1

Funding History

1

Total raised:$170M

Series D$170MUndisclosedFeb 13, 2024

Opportunities

BioAge is positioned to address massive markets by targeting the root causes of metabolic aging.

Its NLRP3 inhibitor has a novel oral approach in diabetic macular edema, and its apelin agonist could solve the critical problem of muscle loss associated with blockbuster GLP-1 obesity drugs, representing a multi-billion dollar combination therapy opportunity.

Risk Factors

The company faces significant clinical trial risk with its novel mechanisms, and its platform's value depends on the success of its lead programs.

As a pre-revenue biotech, it will require additional capital for later-stage trials, risking shareholder dilution, and operates in highly competitive markets.

Competitive Landscape

BioAge competes in the NLRP3 inhibitor space with a differentiated focus on metabolic/ophthalmology indications and in the obesity market as a potential complementary therapy to GLP-1s. Its human-data-first discovery platform provides a unique angle versus competitors relying more on traditional animal model-based research.